生技藥品合約開發市場規模、佔有率和成長分析：按服務、分子類型、開發階段、最終用戶和地區分類－2026-2033年產業預測

2024 年全球生技藥品合約開發市場價值為 145.2 億美元，預計到 2033 年將從 2025 年的 161.9 億美元成長至 388.5 億美元，在預測期（2026-2033 年）內複合年成長率為 11.52%。

全球生物製藥合約開發（CTD）市場正經歷顯著成長，這主要得益於生物製藥需求的不斷成長以及製藥和生物技術公司外包業務的日益普及。推動成長要素包括單株抗體、細胞和基因療法的廣泛應用、生物製程技術的進步以及CTDMO產能的擴張。模組化生產設施和病毒載體生產系統的投資也進一步促進了這一成長。此外，外包單株抗體和疫苗相關專業服務的趨勢也日益明顯。然而，缺乏專業生產能力、營運成本高昂以及複雜的監管要求等挑戰可能會阻礙市場滲透，從而在生物製劑CTD市場中形成一個充滿活力的格局。

全球生物製藥合約開發市場按服務、分子類型、研發階段、最終用戶和地區進行細分。依服務分類，市場分為細胞株開發、製程開發、分析方法開發及製劑開發。按分子類型分類，市場分為單株抗體、疫苗、融合蛋白和基因治療載體。依研發階段分類，市場分為早期（臨床前/I期）及後期（II期/III期）。依最終用戶分類，市場分為大型製藥企業、生技新創公司和學術衍生公司。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球生技藥品合約開發市場的成長要素

全球生物製劑合約開發市場的主要促進因素之一是生物製劑需求的不斷成長，這源於其在治療多種慢性複雜疾病方面的有效性。隨著製藥業向個人化醫療和創新治療方法轉型，對專業合約開發服務的需求也隨之激增。生物製藥研發投入的增加以及對專業知識和基礎設施的嚴格監管要求進一步推動了這一成長。因此，生物技術和製藥公司擴大將生物製藥的開發外包給合約供應商，從而推動了市場擴張並加強了行業內的合作。

全球生技藥品合約開發市場的限制因素

全球生技藥品合約開發（CDO）市場的主要限制因素之一是生技藥品生產和檢測領域複雜而嚴格的法規環境。對安全性、有效性和品質標準的廣泛合規要求，對合約開發機構（CDO）而言是一項重大挑戰。這種複雜性不僅增加了營運成本，還延長了產品開發和核准時間。此外，監管變化和日益嚴格的審查會給CDO帶來不確定性，降低其投資意願，並限制其快速適應市場需求的能力。因此，整個生物製藥CDO產業的成長受到阻礙。

全球生技藥品合約開發市場趨勢

全球生物製藥合約開發市場正經歷著向特定療法專業外包的顯著轉變，這主要受細胞療法、基因療法和雙特異性抗體等複雜生物製藥產品需求成長的驅動。合約開發機構（CDO）正透過利用其科學專長和創新製劑技術來增強自身在這些領域的能力。隨著申辦方越來越重視獨特的專業知識和跨學科方法，能夠提供可擴展解決方案和尖端平台以進行新產品開發的CDO正在獲得競爭優勢。這一趨勢凸顯了戰略夥伴關係關係和先進能力在不斷發展的生物製藥行業中的重要性，而專業公司正在逐步確立其市場領導地位。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球生技藥品合約開發市場規模：依服務分類。

• 細胞株構建
• 製程開發
• 分析與發展
• 配方開發

全球生技藥品合約開發市場規模：依分子類型分類

• 單株抗體
• 疫苗
• 融合蛋白
• 基因治療載體

全球生技藥品合約開發市場規模：依階段分類

• 早期階段（臨床前/I期）
• 後期（II/III期）

全球生技藥品合約開發市場規模：依最終用戶分類

• 大型製藥企業
• 生技新創公司
• 大學創業項目

全球生技藥品合約開發市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Lonza Group
• Catalent Inc.
• Fujifilm Diosynth Biotechnologies
• Samsung Biologics
• WuXi Biologics
• AGC Biologics
• Rentschler Biopharma
• Sartorius AG
• Cytiva（Danaher）
• Thermo Fisher Scientific
• Cobra Biologics（Charles River）
• Boehringer Ingelheim BioXcellence
• KBI BioPharma
• AbCellera Biologics
• ATUM Inc.
• Horizon Discovery（PerkinElmer）
• Just Biotherapeutics（Juno）
• MassBio
• Abzena Ltd.
• Biologics by Design

結論與建議

Global Biologics Contract Development Market size was valued at USD 14.52 Billion in 2024 and is poised to grow from USD 16.19 Billion in 2025 to USD 38.85 Billion by 2033, growing at a CAGR of 11.52% during the forecast period (2026-2033).

The global market for biologics contract development is experiencing significant growth fueled by an escalating demand for biologic therapeutics and increased outsourcing by pharmaceutical and biotechnology firms. Key drivers include the rising adoption of monoclonal antibodies and cell and gene therapies, advancements in bioprocessing technologies, and the expansion of contract development and manufacturing organization (CDMO) capabilities. Investment in modular production facilities and viral vector production systems further supports this growth. Additionally, the trend towards outsourcing specialized services in monoclonal antibodies and vaccines is on the rise. However, challenges such as limited specialized manufacturing capacity, high operational costs, and complex regulatory requirements may hinder market penetration, creating a dynamic landscape for biologics contract development.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biologics Contract Development market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biologics Contract Development Market Segments Analysis

Global biologics contract development market is segmented by service, molecule type, phase, end-user,and region. Based on service, the market is segmented into cell line development, process development, analyticaldevelopment,and formulation development. Based on molecule type, the market is segmented into monoclonal antibodies, vaccines, fusion proteins,and gene therapy vectors. Based on phase, the market is segmented into Early Stage (Preclinical/Phase I) and Late Stage (Phase II/III). Based on end-user, the market is segmented into large pharma, biotech startups,and academic spin-offs. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America,and Middle East & Africa.

Driver of the Global Biologics Contract Development Market

One of the key market drivers for the Global Biologics Contract Development Market is the increasing demand for biologics due to their effectiveness in treating various chronic and complex diseases. As the pharmaceutical industry shifts toward personalized medicine and innovative therapies, the need for specialized contract development services has surged. This growth is further propelled by the rising investment in research and development of biopharmaceuticals, along with stringent regulatory requirements that necessitate expert knowledge and infrastructure. Consequently, biotech and pharmaceutical companies are increasingly outsourcing biologics development to contract providers, enhancing market expansion and fostering collaboration within the industry.

Restraints in the Global Biologics Contract Development Market

One key market restraint for the global biologics contract development market is the complex and stringent regulatory environment governing biologics manufacturing and testing. The extensive requirements for compliance with safety, efficacy, and quality standards can pose significant challenges for contract development organizations (CDOs). This complexity not only increases operational costs but also leads to prolonged timelines for product development and approval. Furthermore, any regulatory changes or increased scrutiny can create uncertainties for CDOs, potentially discouraging investment and limiting their ability to adapt swiftly to market demands, thereby hindering the overall growth of the biologics contract development sector.

Market Trends of the Global Biologics Contract Development Market

The Global Biologics Contract Development market is witnessing a significant shift towards specialized modality outsourcing, driven by the demand for complex biologics such as cell therapies, gene therapies, and bispecific antibodies. Contract development organizations (CDOs) are enhancing their capabilities in these areas, leveraging scientific expertise and innovative formulation techniques. As sponsors prioritize distinct domain knowledge and interdisciplinary approaches, CDOs that can offer scalable solutions and cutting-edge platforms for novel product development are gaining a competitive edge. This trend emphasizes the importance of strategic partnerships and advanced capabilities in the ever-evolving biologics landscape, positioning those with specialization as leaders in the market.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Biologics Contract Development Market Size by Service & CAGR (2026-2033)

• Market Overview
• Cell Line Development
• Process Development
• Analytical Development
• Formulation Development

Global Biologics Contract Development Market Size by Molecule Type & CAGR (2026-2033)

• Market Overview
• Monoclonal Antibodies
• Vaccines
• Fusion Proteins
• Gene Therapy Vectors

Global Biologics Contract Development Market Size by Phase & CAGR (2026-2033)

• Market Overview
• Early Stage (Preclinical/Phase I)
• Late Stage (Phase II/III)

Global Biologics Contract Development Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Large Pharma
• Biotech Startups
• Academic Spin-offs

Global Biologics Contract Development Market Size & CAGR (2026-2033)

• North America (Service, Molecule Type, Phase, End-User)
  • US
  • Canada
• Europe (Service, Molecule Type, Phase, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Service, Molecule Type, Phase, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Service, Molecule Type, Phase, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Service, Molecule Type, Phase, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Lonza Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Diosynth Biotechnologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AGC Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rentschler Biopharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cytiva (Danaher)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cobra Biologics (Charles River)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim BioXcellence
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KBI BioPharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbCellera Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ATUM Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Discovery (PerkinElmer)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Just Biotherapeutics (Juno)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MassBio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abzena Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biologics by Design
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations